State Street’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$309K Sell
97,231
-18,270
-16% -$71.6K ﹤0.01% 3772
2025
Q4
$497K Buy
115,501
+52,637
+84% +$472K ﹤0.01% 3680
2025
Q3
$2.45M Buy
62,864
+21,335
+51% +$607K ﹤0.01% 3264
2025
Q2
$969K Buy
41,529
+36,566
+737% +$865K ﹤0.01% 3491
2025
Q1
$75.5K Hold
4,963
﹤0.01% 4024
2024
Q4
$91.1K Sell
4,963
-48
-1% -$522 ﹤0.01% 4007
2024
Q3
$55.6K Sell
5,011
-11
-0.2% -$129 ﹤0.01% 4083
2024
Q2
$46.6K Sell
5,022
-22,838
-82% -$545K ﹤0.01% 4153
2024
Q1
$913K Sell
27,860
-498
-2% -$12.9K ﹤0.01% 3494
2023
Q4
$759K Buy
28,358
+2,656
+10% +$110K ﹤0.01% 3540
2023
Q3
$1.55M Buy
25,702
+161
+0.6% +$15.1K ﹤0.01% 3420
2023
Q2
$2.6M Sell
25,541
-27,319
-52% -$3.76M ﹤0.01% 3288
2023
Q1
$9.34M Buy
52,860
+3,507
+7% +$1.17M ﹤0.01% 2701
2022
Q4
$19.1M Sell
49,353
-2,826
-5% -$1.07M ﹤0.01% 2273
2022
Q3
$17.6M Sell
52,179
-2,114
-4% -$766K ﹤0.01% 2315
2022
Q2
$17.8M Buy
54,293
+7,610
+16% +$2.67M ﹤0.01% 2334
2022
Q1
$20.4M Buy
46,683
+5,114
+12% +$2.1M ﹤0.01% 2385
2021
Q4
$18.2M Sell
41,569
-213
-0.5% -$107K ﹤0.01% 2542
2021
Q3
$23.2M Sell
41,782
-3,156
-7% -$1.58M ﹤0.01% 2375
2021
Q2
$23.1M Buy
44,938
+19,358
+76% +$12.3M ﹤0.01% 2422
2021
Q1
$20M Sell
25,580
-1,157
-4% -$792K ﹤0.01% 2366
2020
Q4
$14.6M Buy
26,737
+361
+1% +$189K ﹤0.01% 2421
2020
Q3
$12.1M Sell
26,376
-1,469
-5% -$853K ﹤0.01% 2340
2020
Q2
$17.1M Sell
27,845
-518
-2% -$286K ﹤0.01% 2116
2020
Q1
$13.5M Buy
28,363
+594
+2% +$323K ﹤0.01% 2078
2019
Q4
$16.1M Buy
27,769
+2,051
+8% +$1.44M ﹤0.01% 2283
2019
Q3
$16.9M Sell
25,718
-25,209
-50% -$21M ﹤0.01% 2159
2019
Q2
$39.4M Buy
50,927
+1,873
+4% +$1.32M ﹤0.01% 1634
2019
Q1
$34.6M Sell
49,054
-9,924
-17% -$5.94M ﹤0.01% 1675
2018
Q4
$27.6M Sell
58,978
-202
-0.3% -$130K ﹤0.01% 1759
2018
Q3
$51M Buy
59,180
+11,400
+24% +$8.23M ﹤0.01% 1512
2018
Q2
$32.9M Sell
47,780
-25,042
-34% -$12.7M ﹤0.01% 1780
2018
Q1
$32.5M Buy
72,822
+17,857
+32% +$8.66M ﹤0.01% 1724
2017
Q4
$24.2M Sell
54,965
-45,366
-45% -$20.7M ﹤0.01% 1915
2017
Q3
$49.4M Buy
100,331
+10,191
+11% +$5.1M ﹤0.01% 1376
2017
Q2
$49.9M Buy
90,140
+78,675
+686% +$49.9M ﹤0.01% 1352
2017
Q1
$7.59M Buy
11,465
+1,784
+18% +$953K ﹤0.01% 2501
2016
Q4
$3.24M Buy
9,681
+645
+7% +$207K ﹤0.01% 2900
2016
Q3
$2.72M Buy
9,036
+96
+1% +$20.8K ﹤0.01% 2846
2016
Q2
$1.55M Sell
8,940
-64
-0.7% -$13.9K ﹤0.01% 3125
2016
Q1
$2.02M Buy
9,004
+1,149
+15% +$343K ﹤0.01% 3001
2015
Q4
$4.76M Buy
7,855
+614
+8% +$337K ﹤0.01% 2558
2015
Q3
$3.72M Buy
7,241
+3,959
+121% +$2.65M ﹤0.01% 2662
2015
Q2
$1.44M Buy
3,282
+630
+24% +$243K ﹤0.01% 3165
2015
Q1
$959K Sell
2,652
-103
-4% -$39K ﹤0.01% 3231
2014
Q4
$989K Sell
2,755
-45
-2% -$14.5K ﹤0.01% 3266
2014
Q3
$847K Buy
2,800
+127
+5% +$52.1K ﹤0.01% 3292
2014
Q2
$1.64M Buy
2,673
+1,709
+177% +$920K ﹤0.01% 3127
2014
Q1
$647K Buy
+964
New +$570K ﹤0.01% 3323

Other funds holding TVRD

State Street's TVRD Position: Q1 2026 in Review

State Street reduced its Tvardi Therapeutics (TVRD) stake by 16% in Q1 2026, selling an estimated $71.6K and leaving 97,231 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #3772.

State Street first reported a position in TVRD in Q1 2014 and has held it in 49 quarters since. The position peaked at $51M in Q3 2018. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • State Street held 97,231 shares of Tvardi Therapeutics worth $309K as of Q1 2026.
  • State Street sold 18,270 Tvardi Therapeutics shares in Q1 2026, an estimated $71.6K.
  • Tvardi Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3772 holding.
  • State Street first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • State Street's Tvardi Therapeutics position peaked at $51M in Q3 2018.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.